June 6-9, 2016 | San Francisco, CA

Double Helix Sponsor


Schedule at a glance

Register Now



BIO Buzz - Official Show Daily, Brought to you by Alexandria

Health Care


Dave Thomas, Senior Director of Industry Research and Policy Analysis, BIO. BIO Buzz Center 2015
Pamela Gavin, COO, National Organization for Rare Disorders at the BIO Buzz Center 2015
Dr. Eric Topol, Director, Scripps Translational Science Institute, at the BIO Buzz Center 2015
Paul Hastings, OncoMed Pharmaceuticals at the 2015 BIO International Convention
Seema Kumar, Johnson & Johnson at the 2015 BIO International Convention
Dr. Barry Springer, VP of Strategy, Janssen BioTherapeutics, at the BIO Buzz Center 2015
Kimberly Wintenberg, Advanced Plasma Products at the 2015 BIO International Convention
Dr. Francis Kateh, Deputy Minister of Health & CMO, Liberia, at the BIO Buzz Center 2015
Marc Boutin, National Health Council at the 2015 BIO International Convention
Ted Buckley, Head of Government Relations and Public Affairs, Shire Pharmaceuticals
Dr. John Watson, UK Department of Health at the 2015 BIO International Convention
Dr. Robin Robinson, BARDA at the 2015 BIO International Convention

Articles from BioTechNow

WSJ Article Cherry Picks Cost, Ignores Value of Medicines

Publish Date: 10/6/2015, Created By: Jim Greenwood

Today’s Wall Street Journal story, “Price Increases Drive Drug Firms’ Revenue” reaffirms that old chestnut, “…a little information is a dangerous thing…”  When speaking to the complexities of the costs and benefits of America’s healthcare system, a publication like the Wall Street Journal should not cherry pick one aspect of that system to cover while ignoring the rest. Unfortunately and uncharacteristically, in this case, the paper focused on particular costs while ignoring value. In fact, ...

Read More >

Wall Street Journal: The Assault on Drug Innovation

Publish Date: 9/23/2015, Created By: Daniel Seaton

Today, the Wall Street Journal published an editorial commenting on yesterday’s proposed plan by Secretary Hillary Clinton’s campaign to dramatically increase intrusive government regulation of our industry. BIO shared many of the concerns raised by this editorial, concerns which were noted in our statement yesterday. To put into perspective the potential consequences of that proposal, the editorial noted as an example that “Inside of a decade or two, metastatic cancer may become a chronic condition and chemotherapy a relic.” Breakthroughs ...

Read More >

Ezekiel Emanuel’s Flawed Solution

Publish Date: 9/9/2015, Created By: Jim Greenwood

In a New York Times op-ed today, Dr. Ezekiel Emanuel proposes “The Solution to Drug Prices.” The piece is problematic in many respects, but we agree with one of his primary contentions: in discussions about drug prices, value is the real issue. This point was nicely made in a recent Times piece, where it quoted Crystal Bedford, whose five year old daughter, Marley, suffers from a rare genetic disease, Rhizomelic Chondrodysplasia Punctata (RCPD). A treatment ...

Read More >

Rx Response Changes Name to Healthcare Ready

Publish Date: 8/12/2015, Created By: Tracy Cooley

Yesterday, Rx Response announced that its name will be changing to Healthcare Ready. For nearly nine years, Rx Response has helped protect patients’ continued access to medicines in more than 55 different disasters. The rationale for the name change is to better reflect its shifting mission of providing assistance in areas of healthcare outside of medicines and pharmacy. The group has gained significant experience and expertise in ‘coordinating the healthcare system and the public sector during disasters, ...

Read More >

Riding the Bull Market: What’s in Store for Biotech Dealmakers in 2015?

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor

In many ways, 2014 was a record year for biopharma dealmaking, with $355 billion in total transactions, including $53 billion in partnering deals, $16.5 billion in venture investments and 133 IPOs. According to the 2015 Campbell Alliance Dealmakers’ Intentions Study, 2015 is shaping up to be the year of historic M&A in the biopharmaceutical sector, driven in part by greater access to capital. The partnering numbers at BIO 2015 further indicate that the appetite for ...

Read More >

The Next Step: How Companies Build Successful Therapeutic Franchises from the Ground Up

Publish Date: 6/18/2015, Created By: BIOtechNOW Editor

Building a new franchise in a therapeutic from scratch poses a host of challenges, from whether to take the risk of entering a new area at all to whether and how to partner strategically with another company. It’s a challenge for both the biggest biopharma companies and emerging biotechs to evaluate how and when to enter new therapeutic areas and to try to ensure that their efforts will not only help patients in need but ...

Read More >

Wednesday Recap of BIO 2015: What the Official Bloggers Have to Say

Publish Date: 6/17/2015, Created By: Kathryn Mueller

Everyday our BIO Official Bloggers, writers who are on top of the biotechnology beat, release statements about their experience at the BIO International Convention. Here is what they want to share with you today: Scrip Intelligence By Lisa LaMotta Roche’s strong deal-making position is at least partly due to its acquisition of Genentech, but partnering head Sophie Kornowski-Bonnet explained that the firm is more interested in looking for drugs than bolt-on companies. Read more…   ...

Read More >

Dr. Eric Topol’s Insights on Wearables, Smart Phones, Digital Medicine Revolution

Publish Date: 6/17/2015, Created By: Tracy Cooley

Dr. Eric Topol, director of the Scripps Translational Science Institute, is widely recognized for many things: as a renowned cardiologist, #1 Most Influential Physician Executive in the United States by Modern Healthcare, “Rock Star of Science” by GQ, author of several books, and the top authority on digital medicine, but who knew he was also a comedian? Topol shared his views with the BIO 2015 keynote luncheon audience in an informative and humorous way. Using videos ...

Read More >

The Future of Health and Medicine in the Digital Era

Publish Date: 6/17/2015, Created By: Caitlin Kennedy

Dr. Daniel Kraft is a well-known Stanford and Harvard trained physician-scientist and innovator with over 20 years of clinical, research and innovation experience. He serves as Faculty chair for Medicine at Singularity University and is the Founder and Executive Director of Exponential Medicine. Dr. Kraft concluded the Digital Health Forum with his session titled The Future of Health and Medicine: Where Can Technology Take Us? which offered a fast-paced look at the next few years of innovations in ...

Read More >

Complexities of Rare Diseases Take the Spotlight at BIO

Publish Date: 6/17/2015, Created By: Tracy Cooley

Global Genes Founder & CEO Nicole Boice opened the BIO 2015 Orphan & Rare Disease Track by addressing a packed session with a simple, powerful statement: “We’re all working to eliminate the challenges of rare diseases, but patients and their advocates aren’t always equipped to fight.” Organizations like Global Genes help families affected by rare disease by connecting them with much needed tools and resources. By better understanding the definition of a “rare” disease, industry ...

Read More >

Thank you to our 2015 Sponsors

Double Helix Sponsors

Helix Sponsors